Targeted Radiopharmaceuticals: Clinical Advancements in Oncology

The treatment landscape for advanced oncology indications continues to evolve with the development of targeted radiopharmaceuticals. This analysis outlines the documented clinical parameters for two prominent assets in this space: Actinium Pharmaceuticals’ Iomab-B and Radiopharm Theranostics’ 177Lu-RAD202.

---

1. Actinium Pharmaceuticals: Iomab-B (Iodine-131-apamistamab)

Iomab-B is a CD45-targeted radiotherapy designed for conditioning prior to bone marrow transplant (BMT), representing a targeted alternative to standard chemotherapy-based regimens.

Efficacy Data (SIERRA Trial)

Actinium recently presented findings from its pivotal Phase 3 SIERRA trial, which evaluated Iomab-B conditioning against a control arm of conventional physician’s choice salvage chemotherapy for patients with active relapsed or refractory acute myeloid leukemia (r/r AML).

• Durable Complete Remission: The primary endpoint of six-month durable complete remission (dCR) was achieved by 22 percent of patients in the Iomab-B arm, compared to zero percent (0%) of patients in the control cohort (p < 0.0001).
• Event-Free Survival: Patients conditioning with Iomab-B showed a significant improvement in EFS, translating to a 78 percent reduction in the risk of experiencing an event (Hazard Ratio = 0.22).
• Transplant Accessibility: A full 100 percent of patients who successfully received the therapeutic dose of Iomab-B proceeded to bone marrow transplantation, whereas only 18 percent of patients randomized to the control arm were able to access transplant.
• Post-Transplant Response: Post-transplant complete remission was observed in 75 percent of the Iomab-B cohort, compared to 6.3 percent of patients in the evaluable control group.

---

2. Radiopharm Theranostics: 177Lu-RAD202

177Lu-RAD202 is a Lutetium-177 labeled single-domain monoclonal antibody (sdAb) platform engineered to deliver radiotoxic payloads to human epidermal growth factor receptor 2 (HER2) expressing tumors.

Efficacy Data (HEAT Trial)

177Lu-RAD202 is currently being investigated in the ongoing Phase 1 HEAT dose-escalation clinical trial (NCT06824155) in subjects presenting with advanced HER2-positive solid tumors.

• Dose Escalation Milestones: Following favorable data evaluations, the independent Data Safety Monitoring Committee (DSMC) cleared the candidate to transition to the next higher cohort level of 130 mCi.
• Dosimetry Profile: Initial dosimetry calculations verified that absorbed radiation doses across major organ systems remained well within expected, clinically safe operational windows.
• Targeting Localization: Early imaging readouts confirmed clear, tumor-specific localization of the single-domain antibody delivery vehicle with minimal off-target background retention.

---

3. Safety and Tolerability Profiles

Both clinical programs monitor safety parameters closely, looking out for hematologic and radiation-associated toxicity metrics.

Iomab-B Safety Observations

• Sepsis Incidence: In the Phase 3 SIERRA trial, the rate of post-transplant sepsis was significantly lower in the Iomab-B conditioning arm at 6.1 percent, compared to 28.6 percent in the chemotherapy control arm.
• Regimen Tolerability: Lower rates of severe treatment-emergent adverse events, including febrile neutropenia, mucositis, and acute graft-versus-host disease (aGVHD), were observed in patients utilizing the targeted approach.
• Toxicity Management: The targeted localization to CD45-positive cells allowed older, heavily pretreated patients to reach transplant status without experiencing severe systemic organ toxicity.

177Lu-RAD202 Safety Observations

• Dose-Limiting Toxicities: No dose-limiting toxicities (DLTs) have been recorded by investigators across the completed initial dosing cohorts of the HEAT study.
• Discontinuations: Zero patients have tracking events demonstrating treatment discontinuation due to drug-related adverse effects or toxic exposure lines.
• Excretion Kinetics: The single-domain antibody structure demonstrates rapid clearance characteristics, reducing prolonged systemic radiation exposure to healthy tissue matrices.

---

4. Summary Matrix of Clinical Programs

The following ledger distills the operational parameters and clinical statuses for both therapeutic assets. Text has been consolidated to preserve UI integrity on digital dashboards.

Asset	Sponsor	Molecular Target	Clinical Phase	Primary Indication
Iomab-B (Iodine-131)	Actinium Pharmaceuticals	CD45	Phase 3	Relapsed/Refractory AML (Conditioning)
177Lu-RAD202	Radiopharm Theranostics	HER2	Phase 1	HER2-Positive Solid Tumors

Note on Data Interpretation: All clinical response rates, safety metrics, and progression-free survival timelines are drawn directly from published trial cutoffs and corporate disclosures. Cross-trial comparisons should be interpreted with caution due to differences in trial design, patient population, and prior lines of therapy.